# Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients

> **NCT05540184** · PHASE4 · UNKNOWN · sponsor: **Beni-Suef University** · enrollment: 124 (estimated)

## Conditions studied

- AKI - Acute Kidney Injury

## Interventions

- **DRUG:** Trimetazidine 35 mg
- **DRUG:** Allopurinol 300 MG
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT05540184
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-19
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2023-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540184, "Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05540184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*